RNS Number : 2931X
Itaconix PLC
25 April 2023
 

25 April 2023                                                                                                                                              

 

Itaconix plc

("Itaconix" or "the Company")

 

Appointment of Joint Corporate Broker

 

Itaconix plc, a leading innovator in sustainable plant-based polymers used to decarbonise everyday consumer products, is pleased to announce the appointment of Canaccord Genuity Limited as joint corporate broker, to work alongside finnCap, with immediate effect.

 

- Ends -

 

 

For further information please contact:

Itaconix plc

+1 603 775 4400

John R. Shaw / Laura Denner


Belvedere Communications

+44 (0) 20 3008 6864

John West / Llew Angus


finnCap

+44 (0) 20 7220 0500

Nominated Adviser & Joint Broker

Ed Frisby / Abigail Kelly / Milesh Hindocha (Corporate Finance)

Andrew Burdis / Sunila de Silva (ECM)


Canaccord Genuity

Joint Broker

Adam James / Patrick Dolaghan

+44 (0) 20 7523 8000

www.itaconix.com

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products.  The Company's current ingredients are enabling and leading new generations of products in cleaning, hygiene, and beauty.  Itaconix's contributions to the global low carbon economy are recognised by the London Stock Exchange's Green Economy Mark.

https://itaconix.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEAELLAFSDEAA